Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Chronic Rhinosinusitis (Diagnosis)
Interventions: Lactobacillus sakei proBio65, Isotonic Saline Solution; Drug · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Erythema
Interventions: MOB015B, 0.2% SLS, 0.9% Saline, MOB015B vehicle; Drug
Lead sponsor: Moberg Pharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Thyroid Eye Disease, Graves' Orbitopathy
Interventions: Teprotumumab, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more

Conditions: Pelvic Organ Prolapse, Surgery, Postoperative Pain
Interventions: Dexamethasone, Bupivacaine, Bilateral Pudendal Nerve Block, Bilateral Levator Ani Muscle Injection, Saline; Drug · Procedure
Lead sponsor: Lauren Giugale, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: TEPEZZA, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more

Conditions: Dehydration
Interventions: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution; Drug
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Headache
Interventions: Normal Saline 5mL, Normal Saline 20mL/kg, Prochlorperazine 0.15 mg/kg up to 10 mg IV, Diphenhydramine 1 mg/kg up to 50 mg IV; Drug
Lead sponsor: University Medical Center of Southern Nevada; Other
Eligibility: 10 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Postoperative Wound Haemorrhage
Interventions: Tranexamic acid, normal saline; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Decompression Sickness
Interventions: Sodium Chloride 0.9% Inj pre-exposure, Sodium Chloride 0.9% Inj post-exposure, Recombinant human plasma gelsolin pre-exposure, Recombinant human plasma gelsolin post-exposure, Hyperbaric chamber; Drug · Other
Lead sponsor: BioAegis Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Shoulder Arthritis, Blood Loss, Surgical, Tranexamic Acid Adverse Reaction
Interventions: Tranexamic Acid, Normal Saline; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Coronary Artery Bypass, Cardiac Surgical Procedures
Interventions: Thiamine, Normal saline solution; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Subarachnoid Hemorrhage, Acute Kidney Injury
Interventions: Sodium chloride /sodium acetate (16.4%), Sodium chloride (23.4%), PlasmaLyte; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pain, Postoperative, Morbid Obesity
Interventions: Injected bupivacaine post-operatively, Streamed bupivacaine versus streamed normal saline, Aerosolized bupivacaine versus aerosolized saline, Injected lidocaine pre-incision vs saline pre-incision; Drug
Lead sponsor: Pinnacle Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Harrisburg, Pennsylvania

Conditions: Schizophrenia
Interventions: MK-5720, Placebo to MK-5720, MK-8189, Placebo to MK-8189; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Glendale, California • Hallandale, Florida • Hollywood, Florida + 1 more

Conditions: Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone
Interventions: Hydrocortisone, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Hyperpolarized Helium-3, Placebo, Aformoterol; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 50 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Type 2 Diabetes Mellitus, Bone Remodeling
Interventions: exenatide, Saline; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 45 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Infertility of Uterine Origin
Interventions: AMD3100, Normal saline, dilation and curettage; Drug · Procedure
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: San Francisco, California • Basking Ridge, New Jersey • Philadelphia, Pennsylvania

Conditions: Children, Only, Tonsillar Hypertrophy, Adenoid Hypertrophy
Interventions: Lidocaine Iv, Saline Solution; Drug
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 4 Years to 10 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Breast Neoplasms
Interventions: pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more

Conditions: Keloid, Alopecia Areata, Acne, Hypertrophic Scar, Epidermal Inclusion Cyst, Frontal Fibrosing Alopecia, Lichen Plano-Pilaris, Keratoacanthoma, Plaque Psoriasis, Lichen Simplex Chronicus, Prurigo Nodularis, Nummular Eczema, Granuloma Annulare, Morphea, Lichen Planus
Interventions: Corticosteroid with lidocaine, Corticosteroid with normal saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pre-Eclampsia
Interventions: Human Albumin (colloid), Lactated Ringer's Injection (crystalloid), Edwards HemoSphere monitor with ClearSight-Acumen finger cuff; Drug · Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM
Interventions: pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline, pp65-flLAMP DC with GM-CSF; Biological · Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Gainesville, Florida • Orlando, Florida • Durham, North Carolina

Conditions: Aging
Interventions: Esmolol infusion, Saline infusion, Pre exercise baseline, Isometric handgrip exercise, Semi-recumbent cycling; Drug · Other
Lead sponsor: David N. Proctor, PhD; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: University Park, Pennsylvania

Search by objective public record fields.

Topical Probiotic Sinus Irrigations for Treating Chronic Sinusitis

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)

Intravenous Fluids in Benign Headaches Trial

Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery

Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers

Effect of TXA on Blood Loss in Reverse Total Shoulder Arthroplasty

Thiamine as an Adjunctive Therapy in Cardiac Surgery

A Low ChloridE hyperTonic Solution for Brain Edema

Clinical Proposal for the Comparison of Intraperitoneal Anesthetic to Injected Local Anesthetic

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Corticosteroids to Treat Pancreatitis

Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

Endometrial Rejuvenation Study

Lidocaine Infusion for Pain Relief in Children Scheduled for Tonsillectomy and Adenoidectomy

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Pain Outcomes Following Intralesional Corticosteroid Injections

Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion